Emerging biopharma companies account for 72 percent of all late-stage pipeline activity, says IQVIA report

By PharmaCompass

2019-04-25

Impressions: 92 Article

Ongoing changes in the clinical development process are bearing fruit. According to a new report by the IQVIA Institute for Human Data Science, these changes in clinical development have led to a record number of drug approvals in 2018, with 59 novel treatments reaching patients in the United States alone.

IQVIA is a leading global provider of advanced analytics, technology solutions and contract research services to the life sciences industry.

Emerging biopharma companies account for 72 percent of all late-stage pipeline activity, up from 61 percent a decade ago, the report said.

In this new report, titled The Changing Landscape of Research and Development: Innovation, Drivers of Change, and Evolution of Clinical Trial Productivity, IQVIA has put forth a proprietary Clinical Development Productivity Index that reflects changes in trial complexity, success and duration.

Using this index, the report takes a 10-year historical view of these metrics and recasts the data with a future perspective that identifies critical productivity changes expected through 2023.

The report identifies key drivers that are having a quantitative impact on clinical development at a therapy area level. These include digital health technology, patient-reported outcomes, real-world data, predictive analytics and artificial intelligence and biomarker testing.

“As advances in science, technology and data gradually find application within clinical development, the length of time that trials take to complete, the resources required due to trial complexity and likelihood of trial success are all shifting, with impacts varying by therapy area,” said Murray Aitken, IQVIA’s senior vice president.

The PharmaCompass Newsletter – Sign Up, Stay Ahead

Feedback, help us to improve. Click here

Image Credit : #Phisper Infographic by SCORR MARKETING & PharmaCompass is licensed under CC BY 2.0

“ The article is based on the information available in public and which the author believes to be true. The author is not disseminating any information, which the author believes or knows, is confidential or in conflict with the privacy of any person. The views expressed or information supplied through this article is mere opinion and observation of the author. The author does not intend to defame, insult or, cause loss or damage to anyone, in any manner, through this article.”

NEWS

DRUGS & DEVELOPMENTS

MARKET INTEL by PharmaCompass